ArticleOncoimmunology2013
Interferon γ-induced intratumoral expression of CXCL9 alters the local distribution of T cells following immunotherapy with
Article in Oncoimmunology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 33 citations in OpenAlex.
- Trial
- Steroid receptor coactivators: from basic research to translational opportunities.Endocrine reviews · 2026Review
- Steroid receptor coactivators in immunity - From function to emerging translational opportunities.The Journal of biological chemistry · 2026Review
- Stress keratin 17 and estrogen support viral persistence and modulate the immune environment during cervicovaginal murine papillomavirus infection.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity.Molecular therapy oncolytics · 2022Article
- Anti‑VEGF antibody triggers the effect of anti‑PD‑L1 antibody in PD‑L1Oncology reports · 2022Article
- Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment.Frontiers in immunology · 2022Review
- The Cancer Cell Dissemination Machinery as an Immunosuppressive Niche: A New Obstacle Towards the Era of Cancer Immunotherapy.Frontiers in immunology · 2021Review
- Article
- Article
- Advancing CAR T-Cell Therapy for Solid Tumors: Lessons Learned from Lymphoma Treatment.Cancers · 2020Review
- A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy.Frontiers in immunology · 2020Review
- Stress keratin 17 enhances papillomavirus infection-induced disease by downregulating T cell recruitment.PLoS pathogens · 2020Article
- Cancer immunoediting and resistance to T cell-based immunotherapy.Nature reviews. Clinical oncology · 2019Review
- Clonal Deletion of Tumor-Specific T Cells by Interferon-γ Confers Therapeutic Resistance to Combination Immune Checkpoint Blockade.Immunity · 2019Article
- Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells.Frontiers in oncology · 2019Review
- Review
- Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment.Cancer cell · 2017Article
- Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3.Expert review of clinical immunology · 2017Review
- Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration.Nature communications · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
The ability of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.